SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Dostarlimab

Cat. No.:	HY-P99345
CAS No.:	2022215-59-2
Target:	PD-1/PD-L1
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC_{50}s of 1.8 and 1.5 nM, respectively[1].
IC_{50} & Target	IC50: 1.5 nM (PD-L2/ PD-1), 1.8 nM (PD-L1/ PD-1)[1]
In Vitro	Dostarlimab (10-10000 ng/mL) binds to native PD-1 receptor expressed on human and cynomolgus monkey $CD3^+$ T cells in a dose-dependent manner[1]. Dostarlimab (0-375 nM; 48 h) increases IL-2 production with an EC_{50} of approximately 1 nM in a human $CD4^+$ T-cell MLR assay, increases IL-2 production with an EC_{50} of approximately 0.1 nM in staphylococcal enterotoxin B (SEB)-stimulated PBMCs, enhances interferon (IFN)-γ release with an EC_{50} of approximately 0.5 nM[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Dostarlimab (200 μg/mouse; i.p.; twice weekly for 35 days) shows antitumor activity in humanized mouse models[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Humanized NOG-EXL mice, A549 and MDA-MB-436 tumor model[1]
Dosage:	200 μg/mouse
Administration:	Intraperitoneal injection; twice weekly for 35 days
Result:	Resulted in great inhibition of tumor growth in an A549 lung cancer model (tumor growth inhibition [TGI] of 62% at termination). The antitumor activity was associated with a reduction in tumor-associated regulatory T cells and a trend toward increased tumor-infiltrating $CD8^+$ T cells. Inhibited tumor growth of MDA-MB-436 breast cancer model (TGI of 53%).

REFERENCES

[1]. Kumar S, et al. Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models. MAbs. 2021 Jan-Dec;13(1):1954136.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA